68,218 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Bought by Lansforsakringar Fondforvaltning AB publ

Lansforsakringar Fondforvaltning AB publ acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 68,218 shares of the medical equipment provider's stock, valued at approximately $7,206,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Stonebridge Financial Group LLC purchased a new position in Zimmer Biomet in the 4th quarter worth $25,000. Menard Financial Group LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at about $30,000. Accredited Wealth Management LLC bought a new stake in Zimmer Biomet during the fourth quarter worth about $36,000. Kentucky Trust Co bought a new stake in Zimmer Biomet during the fourth quarter worth about $39,000. Finally, OFI Invest Asset Management bought a new stake in Zimmer Biomet during the fourth quarter worth about $40,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Analyst Ratings Changes

ZBH has been the subject of several research reports. Raymond James decreased their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. JMP Securities dropped their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. Truist Financial set a $101.00 price target on shares of Zimmer Biomet in a research report on Tuesday, May 6th. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Morgan Stanley dropped their target price on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Zimmer Biomet has a consensus rating of "Hold" and an average price target of $111.53.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.39% of the stock is currently owned by corporate insiders.

Zimmer Biomet Stock Performance

Shares of ZBH traded down $1.05 during mid-day trading on Monday, reaching $91.12. 1,648,195 shares of the company's stock were exchanged, compared to its average volume of 1,799,596. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock has a market capitalization of $18.03 billion, a PE ratio of 20.48, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The business's fifty day simple moving average is $99.60 and its 200-day simple moving average is $104.59. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.92 and a 52-week high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same period last year, the firm posted $1.94 EPS. Zimmer Biomet's quarterly revenue was up 1.1% on a year-over-year basis. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.05%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.